Experimental Dementia Research Unit, Department of Experimental Medical Science, Lund University, 22184 Lund, Sweden.
MAX IV Laboratory, Lund University, 22100 Lund, Sweden.
Nat Commun. 2017 Mar 13;8:14726. doi: 10.1038/ncomms14726.
Reducing levels of the aggregation-prone Aβ peptide that accumulates in the brain with Alzheimer's disease (AD) has been a major target of experimental therapies. An alternative approach may be to stabilize the physiological conformation of Aβ. To date, the physiological state of Aβ in brain remains unclear, since the available methods used to process brain tissue for determination of Aβ aggregate conformation can in themselves alter the structure and/or composition of the aggregates. Here, using synchrotron-based Fourier transform infrared micro-spectroscopy, non-denaturing gel electrophoresis and conformational specific antibodies we show that the physiological conformations of Aβ and amyloid precursor protein (APP) in brain of transgenic mouse models of AD are altered before formation of amyloid plaques. Furthermore, focal Aβ aggregates in brain that precede amyloid plaque formation localize to synaptic terminals. These changes in the states of Aβ and APP that occur prior to plaque formation may provide novel targets for AD therapy.
降低阿尔茨海默病(AD)大脑中聚集的易聚集 Aβ 肽的水平一直是实验治疗的主要目标。另一种方法可能是稳定 Aβ 的生理构象。迄今为止,由于用于确定 Aβ 聚集构象的脑组织处理的现有方法本身可能会改变聚集体的结构和/或组成,因此大脑中 Aβ 的生理状态仍不清楚。在这里,我们使用基于同步加速器的傅里叶变换红外微光谱、非变性凝胶电泳和构象特异性抗体表明,在形成淀粉样斑块之前,AD 转基因小鼠模型大脑中 Aβ 和淀粉样前体蛋白(APP)的生理构象发生改变。此外,在形成淀粉样斑块之前定位于突触末端的大脑中的局灶性 Aβ 聚集体。在斑块形成之前发生的 Aβ 和 APP 状态的这些变化可能为 AD 治疗提供新的靶点。